| 2026-08-11 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-10 | Deck | Corporate Presentation |
| 2026-08-10 | Press release | Harrow Announces Second Quarter 2026 Financial Results |
| 2026-08-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-10 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-06 | Press release | Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease |
| 2026-08-06 | 8-K | Form 8-K, Item 1.01 |
| 2026-07-27 | Press release | Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 |
| 2026-07-20 | Press release | Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / |
| 2026-07-20 | Press release | Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting |
| 2026-07-01 | Press release | Harrow Announces Commercial Launch of BYOOVIZ® in the United States |
| 2026-06-22 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-10 | Press release | Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Signifi |
| 2026-06-03 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-01 | Deck | 46th Annual Growth Stock Conference |
| 2026-05-27 | Press release | Harrow to Present at William Blair’s 46th Annual Growth Stock Conference |
| 2026-05-13 | Transcript | Q1 FY26 earnings call transcript |
| 2026-05-11 | Deck | Corporate Presentation |
| 2026-05-11 | Press release | Harrow Announces First Quarter 2026 Financial Results |
| 2026-05-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-11 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-27 | Press release | Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-16 | Press release | Harrow Announces the Issuance of J-Code for IOPIDINE® 1% |
| 2026-03-27 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-24 | Press release | Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 |
| 2026-03-24 | 8-K | Form 8-K, Item 8.01 |
| 2026-03-24 | 8-K | Form 8-K, Item 8.01 |
| 2026-03-08 | Deck | Corporate Presentation |
| 2026-03-04 | Press release | Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference |
| 2026-03-02 | Deck | Corporate Presentation · Q4 2025 |
| 2026-03-02 | Press release | Press release · FY 2025 · Mar 2026 |
| 2026-03-02 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-02 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-18 | Press release | Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 |
| 2026-02-02 | Press release | Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth |
| 2026-02-02 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-18 | 8-K | Form 8-K, Item 2.01 |
| 2025-11-10 | Deck | Corporate Presentation |
| 2025-11-10 | 8-K | Form 8-K, Item 2.02 results |